Focus: Cancer Center Featured Story 2

Filters close
26-Apr-2017 9:00 AM EDT
Yale Researchers Identify Optimal Therapy for Patients with Early-Stage Glottic Cancer (Vocal Chord Cancer)
Yale Cancer Center/Smilow Cancer Hospital

Radiotherapy alone is often used to treat early-stage glottic cancer (ESGC), a cancer of the vocal chords, however, the optimal radiation treatment schedule remains unknown, until now.

Released: 25-Apr-2017 3:05 PM EDT
Roswell Park-Led Team Identifies Tumor Marker for Aggressive Ovarian Cancer
Roswell Park Comprehensive Cancer Center

Patients who expressed the tumor antigen NY-ESO-1 had more aggressive cancers and were more likely to die early from their disease, according to a large study conducted by Roswell Park Cancer Institute researchers and published online ahead of print in the journal Gynecologic Oncology.

Released: 24-Apr-2017 4:05 PM EDT
Local Restaurants and Businesses Bring Prom to MD Anderson
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Children’s Cancer Hospital joins Houston restaurants and businesses to host its second annual Prom Party Palooza, a prom for teen cancer patients and their families. The glamorous night takes place at MD Anderson on Saturday, April 29 from 6 to 9 p.m.

19-Apr-2017 2:05 PM EDT
Implanted Scaffold with T Cells Rapidly Shrinks Tumors
Fred Hutchinson Cancer Center

A biopolymer structure enriched with nutrients shows how immunotherapy could be adapted for solid tumors, according to study in The Journal of Clinical Investigation.

18-Apr-2017 2:00 PM EDT
Second Cancers Deadlier in Young Patients
UC Davis Health

Second cancers in children and adolescents and young adults (AYA) are far deadlier than they are in older adults and may partially account for the relatively poor outcomes of cancer patients ages 15-39 overall, a new study by UC Davis researchers has found."Second Primary Malignant Neoplasms and Survival in Adolescent and Adult Cancer Survivors" is published today in JAMA Oncology.

Released: 19-Apr-2017 3:05 PM EDT
Early Tests Show Opdivo Triples Life Expectancy in Lung-Cancer Patients
Yale Cancer Center/Smilow Cancer Hospital

An early round of clinical testing shows that users of Opdivo, a drug sanctioned for treatment of small-cell lung cancer, more than tripled their five-year survival rate beyond the statistical average.

Released: 19-Apr-2017 3:05 PM EDT
Going Viral: Using a Deadly Disease to Kill Ovarian Cancer
Yale Cancer Center/Smilow Cancer Hospital

After studying viruses for 15 years, Dr. Anthony van den Pol believes he has found one that can safely and effectively kill chemotherapy-resistant ovarian cancer.

Released: 19-Apr-2017 12:05 PM EDT
Nine New Disease Sites Added to the NCCN Radiation Therapy Compendium™
National Comprehensive Cancer Network® (NCCN®)

The NCCN Radiation Therapy Compendium™, launched in March 2017, provides a single access point for radiation therapy recommendations within 33 NCCN Guidelines®.

Released: 19-Apr-2017 11:05 AM EDT
Pathologic Complete Response to Neoadjuvant Therapy in Certain Breast Cancer Patients Predicts Low Risk for Local Metastases
University of Texas MD Anderson Cancer Center

Select breast cancer patients who achieved pathologic complete response (pCR) after chemotherapy may be able to avoid follow-up breast and lymph node, or axillary, surgery, according to new findings from researchers at The University of Texas MD Anderson Cancer Center. The study, published today in JAMA Surgery, identifies the exceptional responders who are at lowest risk for local metastases and thereby are candidates for less invasive treatment options.

Released: 19-Apr-2017 10:05 AM EDT
Malaria Drug Successfully Treats 26-Year-Old Brain Cancer Patient
University of Colorado Cancer Center

Small trial uses chloroquine to nix the process of "autophagy" that some cancer cells use to resist treatment, resensitzing glioblastoma to targeted therapy

Released: 19-Apr-2017 10:05 AM EDT
NCCN Survey Reveals Oncology’s Concerns About Financial Distress, Patient Access to Care
National Comprehensive Cancer Network® (NCCN®)

Oncology community professionals are concerned about the ability of their patients to access cancer screening and treatment under the proposed American Health Care Act, according to a survey conducted March 23–25, 2017 at the National Comprehensive Cancer Network® (NCCN®) 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™ at the Rosen Shingle Creek in Orlando, Florida.

Released: 19-Apr-2017 8:00 AM EDT
MD Anderson and Lion Biotechnologies Announce Strategic Alliance to Conduct Clinical Trials of Tils in Multiple Solid Tumors
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center and Lion Biotechnologies, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced a multi-year strategic alliance agreement involving multi-arm clinical trials to evaluate the safety and efficacy of TIL therapy in ovarian, various sarcomas, and pancreatic cancers.

Released: 18-Apr-2017 3:05 PM EDT
Dana-Farber/Harvard Cancer Center Leader Wins 'Reducing Health Disparities Award' From Mass Medical Society
Dana-Farber Cancer Institute

Karen Burns White, Deputy Associate Director of Dana-Farber/Harvard Cancer Center’s (DF/HCC) Initiative to Eliminate Cancer Disparities (IECD) since 2001, has been honored by the Massachusetts Medical Society as the 2017 recipient of the society’s Reducing Health Disparities Award. The honor recognizes an individual who has made outstanding contributions to reducing health disparities due to race, socioeconomic status, age, education, or sexual orientation.

Released: 18-Apr-2017 3:05 PM EDT
Dana-Farber Cancer Institute Named Top 100 Great Hospital in America
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute has been recognized as a “Top 100 Great Hospital in America” by Becker's Hospital Review.

Released: 18-Apr-2017 3:05 PM EDT
Dana-Farber Cancer Institute, Brigham and Women’s Hospital and Harvard Medical School to Convene 2017 Global Health Catalyst Cancer Summit
Dana-Farber Cancer Institute

The Global Health Catalyst Cancer Summit is an annual event that provides a forum for global health stakeholders to network, share knowledge and strengthen high-impact international collaborations that save lives while reducing global health disparities. Participants at the GHC Summit come from all across North America, Europe, Africa, and other impacted nations. Participants include leaders from the World Health Organization, World Bank Group, policy makers, Diaspora organizations, community leaders, U.S. congressional representatives, internationally recognized physicians and researchers, industry, professional sports celebrities and other cancer advocates.

Released: 18-Apr-2017 3:05 PM EDT
Dana-Farber Recognized as National Leader in LGBTQ-Inclusiveness
Dana-Farber Cancer Institute

For the fifth time in five years, Dana-Farber Cancer Institute has been recognized as a leader in LGBTQ Healthcare Equity by the Human Rights Campaign (HRC) Foundation. The distinction is achieved through evaluation by the Healthcare Equality Index (HEI), an annual survey that measures inclusive policies and practices related to LGBT patients, visitors, and staff at nearly 600 medical facilities nationwide.

Released: 18-Apr-2017 9:30 AM EDT
Bridging Health Equity in Our Communities
Rutgers Cancer Institute of New Jersey

During this National Minority Health Month, there is a focus on bridging health equity in our communities including ensuring minority populations have access to high quality cancer screenings and treatments, adequate insurance coverage and other services. Health disparities researcher Jennifer Tsui, PhD of Rutgers Cancer Institute of New Jersey shares some insight.

Released: 17-Apr-2017 3:00 PM EDT
World-Renowned Medical Oncologist Luis Diaz, MD, Named Head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center

Luis A. Diaz, MD, has been named the Head of the Division of Solid Tumor Oncology in the Department of Medicine at Memorial Sloan Kettering (MSK). An accomplished physician, pioneering researcher, and leader in the field of clinical oncology, Dr. Diaz most recently served as an associate professor of oncology at the Johns Hopkins University School of Medicine.

13-Apr-2017 1:05 PM EDT
Nanoparticles Reprogram Immune Cells to Fight Cancer
Fred Hutchinson Cancer Center

Study in Nature Nanotechnology describes new method to transform immune cells, while inside the body, into leukemia-fighting powerhouses

   
Released: 17-Apr-2017 8:00 AM EDT
Swimmers to ‘Splash Away Cancer’ at Annual Event
University of New Mexico Comprehensive Cancer Center

The third annual “Splash Away Cancer!” fundraising event takes place May 20, 2017. All proceeds support patient care and cancer research programs at The University of New Mexico Comprehensive Cancer Center.

Released: 17-Apr-2017 8:00 AM EDT
Cancer Research Institute Appoints Dr. Aiman Shalabi as Chief Medical Officer to Accelerate Precision Immunotherapy Clinical Collaborations
Cancer Research Institute

Nonprofit cancer immunotherapy research organization hires pharmaceutical executive to lead its clinical trials program

Released: 13-Apr-2017 2:05 PM EDT
Quest for Balance in Radiation Leads to Lower Doses
UCSF Helen Diller Family Comprehensive Cancer Center

New UC Project Finds Roadmap to Improve Patient Safety in Radiation Exposure

Released: 13-Apr-2017 2:05 PM EDT
Epidemiological Analysis Shows Unexpected Benefit Related to High Blood Pressure for Many with Ovarian Cancer
Roswell Park Comprehensive Cancer Center

An international team of collaborators retroactively examined the associations between survival among patients diagnosed with invasive epithelial ovarian cancer and those patients’ history of hypertension, heart disease, diabetes, and medications taken for those conditions. They found that while hypertension was linked to better outcomes, diabetes was associated with decreased survival.

Released: 13-Apr-2017 11:00 AM EDT
Are Oncologists Jumping the Gun with the 21-Gene Assay?
National Comprehensive Cancer Network® (NCCN®)

University of Colorado Cancer Center Study uncovers discrepant decision-making for use of 21-gene assay in women with cancer: • Testing occurs in high-risk population, despite current evidence • Non-concordance with NCCN Guidelines® recommendations • Racial and socio-economic disparities found in testing use

Released: 12-Apr-2017 1:30 PM EDT
A Big-Picture Look at the World’s Worst Ebola Epidemic
Fred Hutchinson Cancer Center

An international effort to analyze the entire database of Ebola virus genomes from the 2013-2016 West African epidemic reveals insights into factors that sped or slowed the rampage and calls for using real-time sequencing and data-sharing to contain future viral disease outbreaks.

Released: 10-Apr-2017 10:05 AM EDT
Wistar Scientists Reveal the Role of a Telomere Capping Complex in Cancer
Wistar Institute

Scientists at The Wistar Institute have unveiled part of the protein complex that protects telomeres—the ends of our chromosomes.

   
Released: 7-Apr-2017 8:05 AM EDT
Finding Library Services in Non-Traditional Spaces
Rutgers Cancer Institute of New Jersey

Celebrating all types of libraries during National Library Week (April 9 - 16), Rutgers Cancer Institute of New Jersey is recognizing its own patient resources at its specialized library.

   
Released: 6-Apr-2017 10:05 AM EDT
Study Sheds Light on Role of DNA2 in DNA Repair
Yale Cancer Center/Smilow Cancer Hospital

A biochemical analysis study has discovered a new role for the DNA2 enzyme. The research, which was completed in the lab of Patrick Sung, professor of molecular biophysics and biochemistry at the Yale School of Medicine, looked at the way in which DNA2 repairs breaks in DNA that lead to the abnormalities that cause cancer.

Released: 5-Apr-2017 6:05 AM EDT
Annual Lobos vs. Cancer Gala Celebrates Tenth Year of Fighting Cancer
University of New Mexico Comprehensive Cancer Center

The Lobos vs. Cancer Gala event, which celebrates its tenth year on Saturday, May 20, raises money for cancer research and treatment at UNM Cancer Center.

Released: 4-Apr-2017 4:05 PM EDT
AACR: Phase II Trial Shows Rice Bran Promotes Microbiome Diversity, Slows Growth of Colorectal Cancer Cells
University of Colorado Cancer Center

After 4-week trial of added rice bran, navy bean powder or neither, both the rice bran and navy bean groups showed increased dietary fiber, iron, zinc, thiamin, niacin, vitamin B6, folate, and alpha-tocopherol. The rice bran group also showed increased microbiome richness and diversity. When researchers treated colorectal cancer cells with stool extracts from these groups, they saw reduced cell growth from the groups that had increased rice bran and navy bean consumption.

29-Mar-2017 4:05 PM EDT
Developing Adoptive T-Cell Therapy for Ovarian Cancer
Fred Hutchinson Cancer Center

Dr. Kristin Anderson from Fred Hutch will describe preclinical research on T-cell therapy showing how engineered T cells are able to kill both human and mouse ovarian cancer cells in the lab and significantly extend survival in a mouse model.

3-Apr-2017 4:30 PM EDT
MD Anderson, Oncora Medical Team Up to Fight Cancer with Precision Medicine Alliance
University of Texas MD Anderson Cancer Center

Oncora Medical, a precision radiation oncology software company, and The University of Texas MD Anderson Cancer Center, today announced a strategic alliance focusing on building the next generation of precision medicine software for radiation oncology.

Released: 3-Apr-2017 4:05 PM EDT
Drug Combination Shows Benefit in RAS-Driven Cancers
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute scientists report a number of patients in a small study with RAS-driven lung, ovarian, and thyroid cancers got long-term clinical benefit from a combination of two drugs that targeted molecular pathways controlled by the RAS gene.

Released: 3-Apr-2017 3:05 PM EDT
Drug Combination Boost PARP Inhibitor Response in Resistant Ovarian Cancer
Dana-Farber Cancer Institute

New Dana-Farber study shows patients with platinum resistant ovarian cancer who wouldn’t be expected to respond to a PARP inhibitor had partial shrinkage of their tumor with the addition of a kinase inhibitor.

Released: 3-Apr-2017 2:05 PM EDT
‘Innovator’ Award for New Leukemia Immunotherapies
Fred Hutchinson Cancer Center

Dr. Marie Bleakley, a pediatric oncology physician-scientist at Fred Hutchinson Cancer Research Center, has received a 2017 Innovative Research Grant in immuno-oncology from Stand Up To Cancer.

Released: 3-Apr-2017 1:05 PM EDT
Some Head and Neck Cancer Patients Benefit From Continued Checkpoint Inhibitor Treatment After Tumor Growth
Dana-Farber Cancer Institute

New research suggests that some patients with head and neck cancers can benefit by continuing treatment with an immunotherapy drug after their tumors show signs of enlargement according to investigators at Dana-Farber Cancer Institute and other organizations.

29-Mar-2017 1:00 PM EDT
Deploying an Ancient Defense to Kill Cancer
Fred Hutchinson Cancer Center

What if your body’s ancient defenses against invading bacteria could be hijacked to help kill cancer? In a small sarcoma trial, Fred Hutch scientists led by Dr. Seth Pollack see signs of immune attack after injections of a bacteria-inspired drug.

3-Apr-2017 12:20 PM EDT
Stand Up to Cancer Innovation Grant Funds MD Anderson Microbiome Study
University of Texas MD Anderson Cancer Center

An Innovative Research Grant from Stand Up to Cancer will help a University of Texas MD Anderson Cancer Center physician scientist and her team understand how the bacteria in the digestive tracts of melanoma patients affects their response to a common immunotherapy drug.

Released: 3-Apr-2017 10:00 AM EDT
NCCN Imaging Appropriate Use Criteria Published for 13 Additional Guidelines
National Comprehensive Cancer Network® (NCCN®)

NCCN Imaging AUC™ provide a single access point for all oncology imaging recommendations within the NCCN Guidelines®; currently, NCCN Imaging AUC™ are available for 48 NCCN Guidelines.

Released: 3-Apr-2017 9:30 AM EDT
Examination of Diabetes and Cholesterol Drugs in Pancreatic Cancer Mortality Shows Improved Survival with Use of One More Than the Other
Rutgers Cancer Institute of New Jersey

Research has shown that by themselves, the diabetes drug metformin and cholesterol-lowering drugs known as statins are associated with reduced cancer mortality, but little is known about the effect on pancreatic cancer mortality when these drugs are taken together. Investigators at Rutgers Cancer Institute of New Jersey examined SEER Medicare data to further explore this approach and found that exposure to statins for these patients was significantly associated with reduced overall mortality.

31-Mar-2017 3:00 PM EDT
Memorial Sloan Kettering Expertise on Precision Medicine Highlighted in American Association for Cancer Research Annual Meeting Press Program
Memorial Sloan Kettering Cancer Center

Research findings from Memorial Sloan Kettering Cancer Center (MSK) will be featured in this year’s American Association for Cancer Research (AACR) Annual Meeting press program. The AACR is the oldest and largest professional organization dedicated to advancing cancer research, and the press program highlights cancer research that a panel of AACR experts considers the most significant of the year and deserving of media attention.

Released: 31-Mar-2017 5:05 PM EDT
Beyond Genomics: Using Proteomics to Target Tumors
Fred Hutchinson Cancer Center

Dr. Amanda Paulovich, whose lab has a leading role in the Beau Biden Cancer Moonshot, will speak April 5 at the AACR annual meeting about her lab’s pioneering methods to measure proteins that serve as tumor markers.

Released: 31-Mar-2017 1:05 PM EDT
Two Genes Identify a Subset of HPV+ Head and Neck Squamous Cell Carcinomas with Improved Prognosis
Yale Cancer Center/Smilow Cancer Hospital

A Yale Cancer Center team analyzed HNSCC data from The Cancer Genome Atlas to identify molecular characteristics of HPV+ HNSCC and correlated them with patient outcomes.

Released: 31-Mar-2017 1:05 PM EDT
Chemical Disinfectants and Sanitizers Linked to Thyroid Cancer
Yale Cancer Center/Smilow Cancer Hospital

Workers exposed to chemicals like deodorizers, sanitizers, disinfectants and sterilizers on the job may be more likely than other people to develop thyroid cancer, a recent study suggests.

Released: 30-Mar-2017 10:05 AM EDT
Link between Common Prostate Cancer Treatment, Dementia Detailed in New Study
Perelman School of Medicine at the University of Pennsylvania

A new analysis of patients who have undergone treatment for prostate cancer shows a connection between androgen deprivation therapy (ADT) – a testosterone-lowering therapy and a common treatment for the disease – and dementia, according to researchers from the Perelman School of Medicine at the University of Pennsylvania.

Released: 30-Mar-2017 8:05 AM EDT
Superheroes to Support Cancer Research
University of New Mexico Comprehensive Cancer Center

The Kevin Rudi Foundation will host its third annual Superhero 5K Fun Run to raise money for sarcoma research at The University of New Mexico Comprehensive Cancer Center.

Released: 29-Mar-2017 3:30 PM EDT
Ludwig Scientists Reveal New Advances in Immunotherapy, Biomarkers and Treatment Resistance at 2017 AACR Annual Meeting
Ludwig Cancer Research

Ludwig Cancer Research released today the full scope of advances to be presented by Ludwig researchers at this year’s American Association for Cancer Research (AACR) Annual Meeting in Washington D.C., April 1-5, 2017.

Released: 29-Mar-2017 2:05 PM EDT
Fred Hutch Scientists to Cover Advances in Immunotherapy, Proteomics at AACR
Fred Hutchinson Cancer Center

Scientists from the Fred Hutchinson Cancer Research Center in Seattle are scheduled to present and discuss the latest developments in immunotherapy and proteomics at the American Association for Cancer Research Annual Meeting, Research Propelling Cancer Prevention and Cures, on April 1-5. What follows is a selection of the more than 30 Hutch presentations at the AACR gathering



close
1.7888